Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US FDA's Breakthrough Program Needs Higher Standard For Comparators, NEJM Says

Executive Summary

Harvard Medical School researchers call for inclusion of off-label drugs, accelerated approvals, and dietary supplements in the definition of 'existing therapies.'

Related Content

Nuplazid Safety Review: Blast From the Past Or Preview Of Future Terrors?
Accelerated Approval: US FDA Defends Size Of Premarket Safety Databases, Confirmatory Endpoints
Breakthrough, Fast-Track Pathways Match Their Hype Of Reduced Development Times - JAMA
JAMA Study Continues Wave Of Accelerated Approval Criticism Amid Expansion Of Pathway
NEJM Takes Aim At Expensive Accelerated Approval Drugs Amid Congressional Drug Pricing Debate
Safety Events For Accelerated Approval Drugs Highlighted As Expansion Looms
Mortality In Mind: Survival Analysis Drove Esbriet, Ofev Reviews, If Not Labels


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts